Kornimate/medical-research-clean huggingface dataset:
effect of moxibustion intervention on insomnia patients

Conditions: Insomnia; Moxibustion

Summary: type of study:clinical trial purpose of research:to explore the efficacy and safety of moxibustion combined with traditional chinese and western medicine in treating insomnia. describe participant population/health conditions:120 insomnia patients

type of study:clinical trial purpose of research:to explore the efficacy and safety of moxibustion combined with traditional chinese and western medicine in treating insomnia. describe participant population/health conditions:120 insomnia patients the participants were enrolled according to the principle of randomization and single blindness, and the analysis was adjusted every quarter according to the research schedule. the study group was treated with traditional chinese moxibustion and western medicine. the control group was treated with only western medicine. clinical evaluation of the main efficacy indicators: the score of psqi scale was assessed. the reduction rate of psqi scale was ≥ 25% as effective, and the difference between the two groups was compared as the basis for evaluating the main efficacy indicators. the efficacy of insomnia symptoms was evaluated by the difference of psqi score reduction rate between groups before and after intervention. secondary clinical outcome measures: quality of life scale (sqls), sf-36 scale, clinical gross impression scale (cgi), adverse reaction（tess） .

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of icd-10 insomnia; 2. in line with the relevant diagnostic criteria of tcm syndrome differentiation of heart-spleen and deficiency type insomnia (tcm syndrome diagnosis criteria according to the 1993 ministry of health "guidelines for clinical research on the treatment of insomnia with new chinese medicine" standards: heart-spleen and deficiency: palpitation, amnesia, dizziness, poor and tired, pale face, easy to sweat, tongue, thin coat, thin pulse); 3. pittsburgh sleep quality index (psqi) score \> 7 at baseline; 4. the treatment plan used in this study is tolerable, cooperative and compliant; 5. regardless of gender, age 18-65 years old; 6. understand the procedure and content of the test, and voluntarily sign the informed consent; exclusion criteria: 1. participating in other clinical studies; 2. exclude patients with serious physical diseases or diseases that may affect the evaluation of the test; 3. there is a clear risk of suicide or danger to oneself or others; 4. exclude pregnant or lactating women, or those planning pregnancy; 5. persons with alcohol and drug dependence within 1 year prior to screening.
a study of enasidenib in people with t-cell lymphoma

Conditions: T-cell Lymphoma

Summary: the researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic t-cell lymphoma (aitl) that has an idh2 mutation. the researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.


Eligibility criteria:
inclusion criteria: * pathologically-confirmed aitl at the enrolling institution, with confirmed idh2 mutation (by msk ddpcr). for r/r patients, disease must have relapsed or progressed after at least one systemic therapy, diagnostic tumor samples have at least 5% tumor. i) idh2 hotspot mutation confirmed by cap/clia-certified ngs testing panel. only cases with confirmed mutations detected \>1% vaf will be eligible. * age ≥18 years at time of enrollment previous systemic anti-cancer therapy for aitl must have been discontinued at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment. i) ii) see section 6.2 subject exclusion criteria for guidelines regarding adjuvant and maintenance therapy for prior malignancy. patients who have received localized rt as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the mskcc principal investigator ii) patients who have received localized rt as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the mskcc principal investigator iii) systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment iv) 4) 5) 6) 7) 8) 9) topical steroids for treating cutaneous involvement of aitl is permitted performance status, as assessed in the ecog grading system, ≤2 laboratory criteria (use of gcsf and/or blood product transfusions to reach eligibility criteria must be discussed with the msk pi on a case-by-case basis): exclusion criteria: -

Keywords: enasidenib rituximab idh2-mutant 23-269
hypertension management in family practice

Conditions: Hypertension

Summary: high blood pressure is the greatest threat to the global burden of disease, contributing to an estimated 9.4 million deaths a year. cardiovascular disease morbidity and mortality are positively correlated with the degree of elevation of blood pressure, without any evidence of a threshold down to at least 115/75 mm hg\[2\]. hypertension is common, and nearly every clinician in every specialty deals either directly or indirectly with managing it or its consequences. the population age 65 years or older numbered 46.2 million in 2014 and they represent 14.5% of the us population, the older population in 2030 is projected to be more than twice as large as in 2000, growing from 35 million to 74 million and representing 21 percent of the total u.s. population and it is expected to more than double to 98 million in 2060.proper managing and controlling blood pressure markedly improves patient morbidity and mortality, shep study showed that in persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%.this study will estimate the prevalence of hypertension diagnosis, treatment and outcomes in a family practice population. it is a hypothesis generating study

this a retrospective cross-sectional chart review study. the study population will consist of a random sample of patients from the family practice of the lsu department of family medicine at lsu health sciences center in new orleans (lsuhsc-no) chart data will be collected retrospectively back to one year from date of starting data abstraction. data quality the data used in this study comes from patient charts that are actively being used in the management of patient care. data quality will be ensured through several means. first, the data collection process will be conducted family medicine resident. second, data will be abstracted directly into an electronic encrypted excel file. selection of participants the family medicine residents will take each one 25 patients each and review the charts and record the information on an excel spread sheet.

Eligibility criteria:
inclusion criteria * hypertension exclusion criteria: * no hypertension

Keywords: hypertension
effect of vegetable and fruit enzyme supplementation on muscle activation, aerobic capacity, and blood biochemical parameters after high-intensity interval exercise: feasibility study of exercise design with exergaming

Conditions: Overtraining Syndrome

Summary: this study explores the effectiveness of fruit and vegetable enzyme supplementation in reducing fatigue and enhancing aerobic capacity in elderly individuals after engaging in high-intensity interval exercise (hiie) through exergaming. sixteen elderly female participants were divided into two groups based on pre-test lactate levels: an enzyme group and a placebo group, to ensure comparability. they performed hiie using nintendo switch ring fit adventure, completing eight sets of 20-second high-effort exercises with 30-second rest intervals, totaling 370 seconds of activity. the primary metrics evaluated were blood lactate levels, heart rate (hr), rating of perceived exertion (rpe), and training impulse (trimp). participants in the enzyme group received a fruit and vegetable enzyme supplement in a 30 c.c. dose twice daily for 14 days. the study aimed to determine if enzyme supplementation could effectively mitigate the physiological stress of hiie and improve exercise outcomes in the elderly.


Eligibility criteria:
inclusion criteria: 1. aged 65 and above 2. healthy elderly participants 3. regular exercise habit (3 times per week within the past year) 4. those who can move their upper and lower limbs normally exclusion criteria: 1. no history of upper limb skeletal muscle injury or major injury 2. no heart-related diseases such as high blood pressure 3. no related chronic diseases, such as diabetes
decrease trauma-related shame with virtual reality: the effectiveness of shine-vr

Conditions: Shame

Summary: suffering from ptsd in childhood can have detrimental formative consequences. researchers have been eager to develop effective interventions and to enhance treatment motivation since the introduction of the diagnosis of ptsd in the dsm. with evolving understanding of the disorder, its definition and criteria have changed over the course of time. the most recent change involves the addition of the criterium d of negative affects or emotions in relation to ptsd, the feeling of shame amongst others. individuals experiencing interpersonal trauma, such as sexual abuse, are at high-risk developing trauma-related shame, which in turn can impact the course and effectiveness of ptsd treatment. shame-inducing situations are typically being avoided, and the feelings are not disclosed to peers and other people. hence, acknowledging and sharing feelings of shame as well as practicing self-compassion have been proposed to reduce the impact of that negative self-conscious emotion. these aspects get partially tackled in evidence-based trauma therapies, however, there appears to be a need for a more specific trauma-related shame intervention in addition to existing treatments. recent research has focused on developing such interventions for adults and has reported positive effects. to our knowledge, there is no intervention specifically tackling trauma-related shame in adolescents. virtual reality (vr) is a promising tool for such an intervention. findings suggest that including vr in a treatment results in high treatment satisfaction and that it is highly motivating for its users, which is a crucial component for treatment success. the goal of this study is to test the effectiveness of a short-term vr shame intervention (shine-vr) for adolescents suffering from ptsd after having experienced sexual abuse. the primary objectives of this study to assess the effect of shine-vr on trauma-related shame, self-compassion, and ptsd symptom reduction, to investigate whether treatment motivation, an increase in self-compassion, and a decrease in trauma-related shame are associated with ptsd symptom reduction, and the evaluation of shine-vr by assessing the feasibility of the intervention.


Eligibility criteria:
inclusion criteria: * between 12 and 17 years old at inclusion * interpersonal trauma (sexual abuse); in case of multiple traumas the main trauma should be sexual abuse * indication for ptsd treatment * getting trauma treatment as usual * adequate command of the dutch language exclusion criteria: * known mental disability * epilepsy

Keywords: shame sexual abuse virtual reality self-compassion
screening strategy for early diagnosis of silicosis in at-risk populations in oklahoma

Conditions: Silicosis; Pneumoconiosis; Silica

Summary: silicosis, a preventable yet irreversible occupational lung disease, has an insidious onset with a latency period for diagnosis extending beyond 10 years from the initial exposure. the central hypothesis of this study is that silicosis cases may currently be going undetected. the long-term goal of this research is to determine the current prevalence and forecast the future prevalence of silicosis and other pneumoconiosis among working populations in oklahoma and to assist the public health and the healthcare system in planning for a potential resurgence of silicosis.


Eligibility criteria:
inclusion criteria: * male 30 years or older * past or present employment in dusty environment, exposed to dust at work * ability to consent and answer the questionnaire exclusion criteria: * female * never exposed to dusty environment or never exposed to dust at work * inability to consent and answer the questionnaire * age 29 years or younger

Keywords: silica public health early prevention silicosis screening oklahoma lung disease pulmonology pneumoconiosis lung dust exposure occupational health community health
evaluating possible improvement in tinnitus severity after 28 days dosing of the study drug aut00063 compared to placebo

Conditions: Tinnitus, Subjective

Summary: this study aims to demonstrate that the new medicine aut00063 is effective and safe in the treatment of tinnitus.

reduced activity at certain sites in the brain (called "voltage-gated potassium channels") has been linked to hearing problems, like age-related loss of hearing or tinnitus (a 'ringing' or buzzing noise in the ears). aut00063 is an experimental new medicine that has been developed to improve the action of these specific channels and so treat the brain component of these hearing problems. the main purpose of this study is to try to demonstrate an improvement in the severity of tinnitus after 4 weeks of treatment with the study medicine or the placebo (dummy drug which does not contain the medication). subjects will undergo a safety follow-up after the treatment period. safety and efficacy will be determined by looking at a number of assessments (physical examinations, blood sampling, hearing assessments, questionnaires, etc.) and in case of any serious medical event during the study. the amount of drug in the blood will also be measured. it is expected that up to 152 people with tinnitus may take part in the study. the study participants will be recruited at around 16 hospital sites in the uk.

Eligibility criteria:
inclusion criteria: * english-speaking, who are uk residents registered with a uk general practitioner; * experiencing stable tinnitus (consistent from day to day) * tinnitus has existed for not less than 6 months, and not more than 18 months - contraceptive methods must be used before and for at least 30 days after the stop of the study treatment. exclusion criteria: * severe hearing impairment such that verbal communication is unreliable; * history of important cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases deemed clinically significant at the time of the study by the investigator and which might be jeopardised by entering the study; * moderate or severe depression or generalised anxiety * participation in any clinical research study evaluating another investigational drug or therapy within 30 days of starting the investigational treatment * participation in hearing study, involving an intervention, within 3 months from last study visit; * central nervous system pathologies e.g. multiple sclerosis, parkinson's disease; * tinnitus as a concomitant symptom of a known otological condition (including but not limited to otitis externa, otitis media, otosclerosis, cholesteatoma, ménière's disease or other vestibular problems, acoustic neuroma, or temporo-mandibular joint disorder); * pulsatile tinnitus (rhythmical sounds that often beat in time with the heartbeat); * intermittent tinnitus (comes and goes from one day to the next); * surgery or medical condition that might would be expected to significantly affect absorption of medicines;
sodium excretion of lcz696 in patients with hypertension; heart failure and healthy volunteers

Conditions: Hypertension

Summary: assess mechanism of action of lcz696 related to sodium excretion.


Eligibility criteria:
inclusion criteria: * patients with heart failure: documented nyha class ii-iii heart failure * patients with hypertension: stable hypertensive medication for the preceding 2 months exclusion criteria: * women of childbearing potential * history of recent myocardial infarction * history of dialysis or renal transplant * patients with type 1 diabetes mellitus

Keywords: sodium excretion, lcz696
pain control for intrauterine device placement using paracervical block

Conditions: Pain Due to Intrauterine Contraceptive Device

Summary: intrauterine device (iud) placement can be painful for patients during and after the procedure. fear of pain from iud insertion can be a barrier to obtaining this highly effective long acting reversible contraception. currently there are no proven effective methods for reduction of pain during and after placement of modern iuds. paracervical block pain may decrease this placement pain.

modern iuds are highly effective long acting reversible forms of contraception. the mirena iud is 99.8% effective and the paragard copper iud is 99.2% effective in preventing pregnancy. fear of iud placement can be a barrier to obtaining this highly effective form of birth control. the current standard of care for pain management during and after iud placement is no medication, as randomized control trials published to date have limited data regarding use of medications to decrease pain. there has been one trial to suggest that the use of naproxen with 1% lidocaine paracervical block (pcb) compared to pcb alone may decrease pain after iud placement in primarily nulliparous patients. however, this study was with the much wider and no longer available dalkon shield iud. in addition, this study did not show any significant decrease in pain scores during iud placement. studies to evaluate effectiveness of ibuprofen and misoprostol have shown no significant decrease in pain scores during and after iud insertion, although the majority of participants in these studies were multiparous. there is some suggestion that 2% lidocaine gel one minute prior to iud insertion may have some decrease in pain, although this study was poorly designed. although there is no standard of care in regards to pain medication administration prior to iud placement, providers often suggest paracervical prior iud insertion among nulliparous women. therefore the primary aim of this study is to determine whether a paracervical block (pcb) decreases pain associated with intrauterine device (iud) placement compared to no paracervical block. we hypothesize that administration of a pcb of 20 ml 1% buffered lidocaine prior to iud placement will decrease pain scores by at least 20mm on a visual analog scale at various time points during iud placement when compared to no paracervical block.

Eligibility criteria:
inclusion criteria: * nulliparous women * english or spanish speaking * present for intrauterine device placement for contraception or menorrhagia (in the case of mirena iud insertion). exclusion criteria: * pregnancy * any diagnosed chronic pain issues (i.e. fibromyalgia, endometriosis, dysmenorrhea, irritable bowel syndrome, interstitial cystitis) * if the patient has taken any pain medications within 6 hours of enrollment, including aspirin or other nsaids * misoprostol administration within 24 hours of enrollment * history of prior iud insertion * known contraindications to iud

Keywords: contraception pain intrauterine device paracervical block
evaluation of a venous-return assist device (venowave) to treat post-thrombotic syndrome: a randomized controlled trial

Conditions: Postphlebitic Syndrome

Summary: the purpose of this study is to determine whether daily use of a lower limb venous-return assist device, "venowave', improves leg symptoms, ability to perform activities of daily living, and quality of life in subjects with severe pts.

eligible consenting patients will be randomly allocated to receive either the veno-device (active or placebo for 8 weeks and crossed over for a further 8 weeks (active or placebo) following a 4 week 'wash out' period.( a randomized controlled 'crossover' study}

Eligibility criteria:
inclusion criteria: * past history of objectively documented deep vein thrombosis * daily leg swelling with discomfort (i.e. report at least one of the following symptoms: heavy legs, aching legs and/or throbbing) for a minimum of 6 months * over 18 years of age (and of either gender). * villalta score of greater than 14(i.e.severe post phlebitic syndrome) exclusion criteria: * episode of objectively documented deep vein thrombosis occurred less than 6 months before recruitment * subjects report that their symptoms have been unstable (worsening, improving or variable over the previous month). * active venous ulceration * baseline leg circumference greater than 50 cm (cuff will not fit subject) * symptomatic peripheral arterial disease peripheral neuropathy

Keywords: pts post phlebitic syndrome activities of daily living quality of life
effect of dissecting of the inferior pulmonary ligament on postoperative pulmonary reexpansion and recurrence

Conditions: Pneumothorax

Summary: this subject analysis of the influence of the dissociating inferior pulmonary ligament on pulmonary reexpansion and recurrence in the treatment of primary spontaneous pneumothorax by video assisted thoracic surgery. all patients are randomly divided into two groups: group a and group b. wedge resection(wr) will be performed for all patients. investigators dissect the inferior pulmonary ligament(dipl) for group a. investigators do not dissect the inferior pulmonary ligament for group b. the pulmonary reexpansion and recurrence rate are observed between the two groups.

wedge resection of the lung is usually used in the treatment of primary spontaneous pneumothorax. and the pleural treatment also might be used. but part of secondary pneumothorax patients who had undergone surgical, the bullae can be found especially in the apical of lung, even if the pleural have been treated in some way.this subject provides a new way of thinking and method to solve the problem of recurrent spontaneous pneumothorax.

Eligibility criteria:
inclusion criteria: 1. the patients diagnosis pneumothorax with chest radiograph or computed tomography (ct) 2. the clinical and final pathological diagnosis for patient is psp. 3. the patients with stable vital signs, no contraindication for operation and no communication barriers. 4. the patients,after informed of test content, significance and risk, who voluntarily enroll and sign informed consent. exclusion criteria: 1. the patients who refuse to do a video assisted thoracic surgery. 2. the patients with pneumothorax with specific causes such as pulmonary hamartoangiomyomatosis, catamenial pneumothorax, and pneumothorax secondary to chronic obstructive pulmonary disease. 3. the patients who were older than 50 years 4. the patients with familial history of pneumothorax. 5. the patients with mental disorders, low intelligence quotient, can not objectively reflect the indicators of observation. 6. the patients who refuse to follow-up.

Keywords: prime spontaneous pneumothorax recurrence